Home / Health / New Diabetes Pill Outperforms Existing Options
New Diabetes Pill Outperforms Existing Options
26 Feb
Summary
- New oral medication orforglipron shows superior weight loss.
- Pill offers significant blood sugar control without food restrictions.
- Study involved 1,500 participants across multiple countries.
A significant breakthrough in type 2 diabetes management has been announced with the study of a new once-daily oral medication, orforglipron. Researchers found this new pill to be more effective than existing tablet-based GLP-1 receptor agonists in controlling blood sugar levels.
Furthermore, the study highlighted orforglipron's superior impact on weight loss. Participants taking orforglipron lost between six and eight percent of their body weight, compared to four to five percent for those on the current oral semaglutide. The new drug also offers a key advantage: it can be taken without strict food or water intake guidelines.
The international study involved 1,500 individuals with type 2 diabetes not adequately controlled by metformin. Conducted across medical centers in Argentina, China, Japan, Mexico, and the US, the year-long trial compared different dosages of orforglipron and oral semaglutide.
While both drugs showed effectiveness, orforglipron was noted for its simple dosing and potential to overcome barriers associated with injectable therapies. Researchers indicated that gastrointestinal issues were the most frequently reported side effects for orforglipron, with more participants reporting them compared to the semaglutide group.
